Teva strikes Celebrex deal with Pfizer; Abbott hot on acquisitions; ex-Sanofi exec sentenced to 16 months;

@FiercePharma: Tops on FP yesterday: Novartis marks 235 admin jobs for deletion amid companywide restructuring. Story | Follow @FiercePharma

@TracyStaton: ICYMI: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. Report | Follow @TracyStaton

@EricPFierce: FDA says import alert for saline made at Baxter plant in Canada has no connection to shortage in U.S. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Our newest special report is live! Top 10 M&A deals of 2013. Feature | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) says it has settled a patent lawsuit with Pfizer ($PFE) that will allow it to launch a generic of Pfizer's blockbuster painkiller Celebrex in December. Story

> Abbott Laboratories ($ABT) CEC Miles White says the company is working on some acquisitions Story (reg. req.)

> Jacques Servier, founder of the French drugmaker that bore his name, has died at the age of 93, living long enough to see his company prosecuted over Mediator drug, the side effects of which were tied to the deaths of 2,000 people in France. Story

> A California legislator has given up this year on a bill to make the drug industry pay for the state's drug disposal programs. Report

> A former Sanofi ($SNY) executive who cooperated with prosecutors after pleading guilty to insider trading has been sentenced to 16 months in prison. Story

> Actelion ($ACTL) pointed to Opsumit, its new pulmonary arterial hypertension (PAH) for the reason it turned in better than expected Q1 earnings. Story

Medical Device News

@FierceMedDev: ForSight Vision5 ropes in $15M in Series C financing to develop its intraocular therapy. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Abbott's device sales slip as diagnostics keeps revenue rolling. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Boston Scientific scores FDA approval for a new crop of implantable cardiac devices. More | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Convergent Dental pockets $8M for 'dread-free' laser. Story

> Foundation Medicine ditches plans to raise $150M. Item

> Endo's AMS hit with an FDA warning letter. News

> Report: Surgical device maker Conmed shopping itself around. More

Biotech News

@FierceBiotech: AMRI plans to shutter an R&D shop to save cash. Story from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Pfizer, AstraZeneca back a new strategy for cancer drug R&D. Article | Follow @JohnCFierce

@DamianFierce: FDA sends out obscure notice that it'll discuss a "Safety Communication on the use of a device for a certain medical procedure" at 1. | Follow @DamianFierce

@EmilyMFierce: Latest WHO update on Ebola outbreak in Western Africa: 224 cases, including 135 deaths. More | Follow @EmilyMFierce

> GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks. More

> Biotech upstart grabs $18M to study a new drug to protect pregnancies. Report

> Vital Therapies banks $54M in a downsized IPO retry. Article

> Which therapies top Thomson Reuters' list of new drugs to watch this year? Story

Pharma Manufacturing News

> Novartis' Sandoz unit recalls some Ritalin over packaging issue. Article

> Bill for California statewide disposal law lands in the trash. Story

> Counterfeits of Roche's Herceptin found in EU supply chain. More

> Novartis' Alcon opens $160M plant in Singapore. News

> U.K. starts work on $64M biologics manufacturing center. Report

Vaccines News

> Ebola deaths rise to 135 as vaccine research lags. Report

> Merck, Sanofi hope for sales expansion with two-dose Gardasil switch. Story

> Whooping cough mutations may be weakening vaccine effectiveness. More

> New Novartis director will implement Bexsero on U.K. immunization program. Item

> Dynavax initiates PhIII study it hopes will quell FDA's safety concerns. Article

And Finally... Complications from diabetes, especially deaths from heart attacks, have fallen sharply in the last 20 years even as the number of patients suffering from the condition has skyrocketed, a new report shows. Story (sub. req.)

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…